

Untitled

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSS? ### Status: Signing onto Dialog *****

ENTER PASSWORD:

***** HHHHHHHH SSSSSSS? *****

welcome to DIALOG

Status: Login successful dialog level 05.20.01D

Last logoff: 04jan08 10:59:57

Logon file1 08jan08 12:42:27

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***BIOSIS Previews Archive (File 552)

***BIOSIS Previews 1969-2007 (File 525)

***Trademarkscan - South Korea (File 655)

RESUMED UPDATING

***File 141, Reader's Guide Abstracts

RELOADS COMPLETED

***Files 72 & 73, EMBASE

***Files 340, 341 & 942, CLAIMS/U.S. Patents - 2006 reload now online

NEWS

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<
>>>and events, please visit what's New from Dialog at <<
>>><http://www.dialog.com/whatsnew/>. You can find news about<<
>>>a specific database by entering HELP NEWS <file number>. <<

* * *

File 1:ERIC 1965-2007/Nov
(c) format only 2007 Dialog

Set Items Description

--- -----

Cost is in DialUnits

?

Terminal set to DLINK

? B MEDICINE

>>> 138 is unauthorized

>>>1 of the specified files is not available

08jan08 12:42:49 User294085 Session D153.1

\$0.50 0.141 DialUnits File1

\$0.50 Estimated cost File1

\$0.10 TELNET

\$0.60 Estimated cost this search

\$0.60 Estimated total session cost 0.141 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1926-2008/Dec W5

(c) 2008 The Thomson Corporation

File 34:SciSearch(R) Cited Ref Sci 1990-2008/Jan W1

Untitled

File 35:Dissertation Abs Online 1861-2007/Oct
 (c) 2007 ProQuest Info&Learning
File 45:EMCare 2008/Dec W5
 (c) 2008 Elsevier B.V.
File 65:Inside Conferences 1993-2008/Jan 08
 (c) 2008 BLDSC all rts. reserv.
File 71:ELSEVIER BIOBASE 1994-2007/Dec W5
 (c) 2007 Elsevier B.V.
File 73:EMBASE 1974-2008/Jan 04
 (c) 2008 Elsevier B.V.

*File 73: The file has been reloaded and accession numbers have changed. See HELP NEWS 72 for details.

File 91:MANTIS(TM) 1880-2007/Apr
 2001 (c) Action Potential

*File 91: This database has stopped updating temporarily. Please see HELP NEWS 91 for details.

File 98:General Sci Abs 1984-2007/Dec
 (c) 2007 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2007/Dec W5
 (c) 2007 NewsRx

File 144:Pascal 1973-2007/Dec W2
 (c) 2007 INIST/CNRS

File 149:TGG Health&Wellness DB(SM) 1976-2008/Dec W4
 (c) 2008 The Gale Group

File 155:MEDLINE(R) 1950-2008/Dec 06
 (c) format only 2008 Dialog

*File 155: MEDLINE has ceased updating with UD20071203. Please see HELP NEWS 154 for details.

File 156:ToxFile 1965-2007/Nov W2
 (c) format only 2007 Dialog

*File 156: Please see HELP NEWS 156 for information on changes to updating beginning in November.

File 159:Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog

File 162:Global Health 1983-2008/Dec
 (c) 2008 CAB International

File 164:Allied & Complementary Medicine 1984-2008/Jan
 (c) 2008 BLHCIS

File 172:EMBASE Alert 2008/Dec 18
 (c) 2008 Elsevier B.V.

File 266:FEDRIP 2007/Oct
 Comp & dist by NTIS, Int'l Copyright All Rights Res

File 369:New Scientist 1994-2007/Sep W4
 (c) 2007 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
 (c) 1999 AAAS

*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2007/UD=14725
 (c) 2007 AMERICAN CHEMICAL SOCIETY

*File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 2006 The Thomson Corp

File 444:New England Journal of Med. 1985-2007/Nov W2
 (c) 2007 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.

Set Items Description

--- -----

? S VIBRIO ADJ CHOLERA; S TABLET

Untitled

S1 0 VIBRIO ADJ CHOLERA
S2 120459 TABLET
? S VIBRIO (W)CHOLERA
111474 VIBRIO
51991 CHOLERA
S3 49490 VIBRIO (W)CHOLERA
? S S2 AND S3
120459 S2
49490 S3
S4 37 S2 AND S3
? RD
S5 22 RD (unique items)
? T S5/K/ALL
>>>KWIC option is not available in file(s): 399

5/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: cholera vaccine to avoid that inconveniences during application. We have therefore compared inactivated cultures of vibrio cholerae with tablets formulation vaccine. We obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of V cholerae inactivated cell remained unaltered in the final tablet formulation. The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable...

DESCRIPTORS:

...ORGANISMS: Vibrio cholerae (Vibrionaceae)

5/K/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Removal of Salmonella typhi, Shigella dysenteriae, Vibrio cholerae and rotavirus from water using a water treatment tablet

DESCRIPTORS:

...ORGANISMS: Vibrio cholerae (Vibrionaceae)

5/K/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...ABSTRACT: or may not be produced: P. inconstans. Profile 6: produces only citrase: Pseudomonas, Alcaligenes, Salmonella, Vibrio cholerae , Escherichia freundii and E. intermedia. Profile 7: does not produce citrase and urease: E. coli...

...pathogen which may become more resistant to drugs. Chlormerodrin is given in doses of one tablet 4 times daily for 4 days in 2 series of patients. In one group of...

DESCRIPTORS:

...ORGANISMS: Vibrio cholerae (Vibrionaceae)

5/K/4 (Item 1 from file: 45)
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

DESCRIPTORS:

Bangladesh; Vibrio cholerae ; antibiotic resistance; bacterium isolation ; clinical trial; confidence interval; dehydration; diarrhea; disease duration; disease severity; drug...

...analysis; hospital admission; human; oral rehydration therapy; relapse;

Untitled
short survey; single drug dose; statistical significance; tablet formulation; treatment outcome; vomiting; antibiotic agent; placebo

5/K/5 (Item 2 from file: 45)
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

...antigens. Conclusion: Microencapsulation appears to be a suitable approach for oral vaccination against ETEC and *Vibrio cholerae*.

DESCRIPTORS:

...linked immunosorbent assay; immune response; Western blotting; microencapsulation; adrenal cell; vaccination; antibody detection; enteric coated tablet; animal model; animal experiment; nonhuman; Gram negative infection; steroidogenesis; whole cell; *Vibrio cholerae*; digestion; bacterium; immunization; intestine lymphatic tissue; heat

5/K/6 (Item 1 from file: 135)
DIALOG(R)File 135:(c) 2007 NewsRx. All rts. reserv.

... 6AU, England. david.hill@uclh.org.

Study 2: An inactivated cholera vaccine developed in oral tablet formulation is antigenic and immunogenic.

According to recent research published in the journal *Vaccine*, "Licensed..."

...cholera vaccine to avoid that inconveniences during application."

"We have therefore compared inactivated cultures of *Vibrio cholerae* with tablets formulation vaccine.

"We obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of *V. cholerae* inactivated cell remained unaltered in the final tablet formulation," said A. Talavera and colleagues at Finlay Institute in Cuba.

The authors concluded, "The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable..."

...from China, "The cholera toxin (CT) genes ctxAB are carried on a lysogenic phage of *Vibrio cholerae*, CTX Phi, which can transfer ctxAB between toxigenic and nontoxigenic strains of bacteria. This transfer...

...kanb@btamail.net.cn.

Keywords: Beijing, China, Cholera vaccine, Vaccine Development, Vaccine Efficacy, Immunology, Immunotherapy, *Vibrio cholerae*, Proteomics.

This article was prepared by Gastroenterology Week editors from staff and other reports. Copyright...

...DESCRIPTORS: U.K.; Preventive Medicine; Proteomics; Travel Health; Travel Immunization; Travel Vaccination; Vaccine Development; Vaccine Efficacy; *Vibrio cholerae*; All News

5/K/7 (Item 2 from file: 135)
DIALOG(R)File 135:(c) 2007 NewsRx. All rts. reserv.

Inactivated cholera vaccine in oral tablet form is antigenic and immunogenic

TEXT: An inactivated cholera vaccine developed in oral tablet formulation is antigenic and immunogenic.

According to recent research published in the journal *Vaccine*, "Licensed..."

Untitled

... cholera vaccine to avoid that inconveniences during application." "we have therefore compared inactivated cultures of Vibrio cholerae with tablets formulation vaccine.

"we obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of V. cholerae inactivated cell remained unaltered in the final tablet formulation," said A. Talavera and colleagues at Finlay Institute in Cod.

The authors concluded, "The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable...

...the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England.

Keywords: Cod, Cuba, Cholera Vaccine, Vibrio Cholerae , Oral Tablets, Immunogenic & Antigenic.

This article was prepared by Anti-Infectives Week editors from staff

...

DESCRIPTORS: Cholera Vaccine; City: Cod; Country: Cuba; Finlay Institute, Havana; Immunogenic & Antigenic; Immunology; Oral Tablets; Vibrio Cholerae ; All News; Professional News; All News; Professional News

5/K/8 (Item 1 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... cause of strep throat, scarlet fever, pneumonia, and, most recently, gruesome "flesh eating" infections; and Vibrio cholerae , the cause of cholera. And tuberculosis is back. Antibiotic-resistant strains of the TB bacterium...a skin infection, phage can be applied to the spot. We have developed aerosol and tablet preparations. Also, the institute has worked out a special phage remedy against staphylococcal infections. It...

5/K/9 (Item 2 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... 10.sup.6] organisms. As it takes [10.sup.8] organisms of E coli or vibrio cholerae , [10.sup.5] of salmonella, and 10- [10.sup.2] of shigella to cause disease...Helminger A, Witassek F, Manhart MD, et al. Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agent Chemother 1986;29:625-7. [3] Sox TE, Olson

...

5/K/10 (Item 3 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... the world is unknown.

Other potential bacterial pathogens, including Aeromonas hydrophila, Yersinia enterocolitica, Pleisiomonas shigelloides, Vibrio cholerae (non-O1), and Vibrio fluvialis, are known to cause diarrhea in children and adults. In...active agents and mode of action of bismuth subsalicylate remain to be elucidated, and the tablet form of the drug requires further evaluation.

7. A better understanding of the neurohumoral control...

5/K/11 (Item 4 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... Enteroinvasive E. coli	Uncommon
Enterohemorrhagic E. coli	Uncommon

Page 5

<i>Shigella</i> species	Untitled
<i>Salmonella</i> species	Less common
<i>Vibrio cholerae</i>	Uncommon
<i>Campylobacter jejuni</i>	Less common
<i>Clostridium difficile</i>	Uncommon
<i>Aeromonas hydrophila</i>	Uncommon
Viruses	
<i>Rotavirus</i>	Uncommon
Norwalk...	

...mechanisms of enterotoxins and cytotoxins result in distinctive clinical syndromes.

Enterotoxins that are elaborated by *Vibrio cholerae* and enterotoxigenic *Escherichia coli* cause large-volume watery diarrhea without systemic symptoms. Rice-based rehydrating...one of the following may be used in adult patients:

- Ciprofloxacin (Cipro), one 500-mg tablet or two 250-mg tablets per day
- Norfloxacin (Noroxin), one 400-mg tablet per day
- Trimethoprim-sulfamethoxazole, double strength (Bactrim DS, Cotrim D.S., Septra DS), one tablet per day
- Bismuth subsalicylate (Pepto-Bismol), two tablets four times daily

TABLE 5

Empiric Therapy...

...drinks or bottled water and should eat salted crackers.

Antibiotics(*)

Ciprofloxacin (Cipro), one 500-mg tablet or two 250-mg tablets twice daily for three days

or

Norfloxacin (Noroxin), one 400-mg tablet twice daily for three days

or

Trimethoprim-sulfamethoxazole, double strength (Bactrim DS, Cotrim D.S., Septra DS), one tablet twice daily for three days

Antimotility medications

Loperamide (Imodium), two 2-mg tablets after the first loose stool, then one tablet after each loose stool, for a maximum of 16 mg in 24 hours

or

Diphenoxylate...times daily, decreased the incidence of diarrhea by 60 percent, while the use of one tablet four times daily reduced the incidence of diarrhea by only 40 percent. However, use of...

5/K/12 (Item 5 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

...useful against *M catarrhalis* infection include combinations of trimethoprim and sulfamethoxazole, one double-strength (DS) tablet twice daily; and of amoxicillin and clavulanate, 250 to 500 mg three times daily.

What...of primary or recurrent *P carinii* pneumonia complicating AIDS.

Untitled

The usual dosage is one DS tablet given twice daily, although many physicians find that one DS tablet given for 3 consecutive days each week provides excellent protection with less toxicity.

Are there...

...tolerate drugs in either of the other regimens. A combination of sulfadoxine and pyrimethamine, one tablet weekly, has been used to prevent *P carinii* pneumonia, but it does not appear to...

...pathogens

<i>Aeromonas hydrophila</i>	<i>Salmonella enteritidis</i>
<i>Bacteroides fragilis</i>	<i>Staphylococcus aureus</i>
<i>Chromobacterium violaceum</i>	<i>Streptococcus sp</i>
<i>Clostridium perfringens</i>	<i>Vibrio cholerae</i>
<i>Erysipelothrix rhusiopathiae</i>	<i>Vibrio mimicus</i>
<i>Escherichia coli</i>	<i>Vibrio parahaemolyticus</i>
<i>Myobacterium marinum</i>	<i>Vibrio vulnificus</i>
<i>Pseudomonas aeruginosa</i>	
when...	

5/K/13 (Item 6 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... here are fully aware of their responsibility as the Caribbean islands' main defence line against *Vibrio cholerae*. Their first concern is the fact that up to 50% of people incubating the disease...

...drug regulatory agency (BGA) felt that a temporary suspension could not be justified. The 20 tablet pack, however, was withdrawn, reinforcing the time limit of use (10 tablet pack for 10 days) for the second most prescribed hypnotic drug in Germany. But patients...

5/K/14 (Item 7 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... 15 years, just a few bacteria (*Enterotoxigenic Escherichia coli*, *enteropathogenic E coli*, *Shigella spp*, and *Vibrio cholerae O1*) and one virus (*rotavirus*) combine to cause a substantial proportion of the diarrhoeal illness...

...or placebo within one week; [2] a few minutes beforehand they chewed a 1 g tablet of [NaHCO₃] to neutralise gastric acid. During 3 years of surveillance, protective efficacy...

5/K/15 (Item 8 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

...ABSTRACT: to the World Health Organization by 35 countries. Untreated cholera, due to various strains of *Vibrio cholerae O1* (VC), can result in fatality rates of 40 percent. It is estimated that more...

... effective oral vaccines based on nonliving organisms and antigens, or on live, attenuated strains of *Vibrio cholerae O1*. the meeting discussed the results that have recently emerged from such studies, including a...

...immune response against one or more relevant antigens of *V. cholerae O1*.
Important antigens of *Vibrio cholerae O1*
Studies in animals and humans have shown that *V. cholerae* cell-wall lipopolysaccharide (LPS...or hyper-produce the B subunit. a practical vaccine formulation, possibly a capsule or soluble tablet that is stable

Untitled
at ambient temperatures, should be developed.
Live oral cholera vaccine. The objective...

5/K/16 (Item 1 from file: 155)
DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

Diagnostic antigens and antisera in tablet form.
...; *Salmonella paratyphi A*--immunology--IM; *Salmonella paratyphi B*--immunology--IM; *Salmonella typhi*--immunology--IM; Tablets; *Vibrio cholerae*--immunology--IM

5/K/17 (Item 2 from file: 155)
DIALOG(R)File 155:(c) format only 2008 Dialog. All rts. reserv.

... administration exceeded the dose required for subcutaneous application. Fraction I should be used for Producing tablet form of cholera vaccine because it was least toxic and provided the greatest yield.

Descriptors: *Antibodies, Bacterial--biosynthesis--BI; *Antigens, Bacterial; *Antitoxins--analysis--AN; *Cholera Vaccines; *Toxoids; *Vibrio cholerae --immunology--IM

5/K/18 (Item 1 from file: 266)
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

Development of Crofelemer to Treat *Vibrio cholerae*
...SUMMARY: and manufacture a new oral dosage form that has a better dissolution profile than the tablet currently used for clinical trials for other indications. Without this improved dosage form, the cholera...
? S K/3/1,7 AND 6

0 K/3/1,7
12593202 6
S6 0 K/3/1,7 AND 6
? T S5/3/1,7 AND 6
>>>'AND' not allowed in command
? T S5/3/1,7, 6

5/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19077817 BIOSIS NO.: 200600423212
Formulation in tablets of a cholera whole cells inactivated vaccine candidate
AUTHOR: Talavera A (Reprint); Ano G; Pino Y; Castano J; Uriarri E; Riveron L; Gil S; Fernandez S; Cedre B; Valmaseda T; Perez J L; Infante J F; Garcia L; Sierra G
AUTHOR ADDRESS: Finlay Inst, 27 Ave 19805, La Lisa, Ciudad La Habana, AP 16017, Cod 11600, Cuba**Cuba
AUTHOR E-MAIL ADDRESS: atalavera@finlay.edu.cu
JOURNAL: Vaccine 24 (16): p3381-3387 APR 12 2006 2006
ISSN: 0264-410X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

5/3/7 (Item 2 from file: 135)
DIALOG(R)File 135:NewsRx Weekly Reports
(c) 2007 NewsRx. All rts. reserv.

Untitled

0000309900 (USE FORMAT 7 OR 9 FOR FULLTEXT)
Inactivated cholera vaccine in oral tablet form is antigenic and
immunogenic
Anti-Infectives week, June 19, 2006, p.16

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 253

5/3/6 (Item 1 from file: 135)
DIALOG(R)File 135:NewsRx Weekly Reports
(c) 2007 NewsRx. All rts. reserv.

0000331228 (USE FORMAT 7 OR 9 FOR FULLTEXT)
Findings from the United Kingdom, Cuba and People's Republic of China
describe new data in cholera research
Gastroenterology week, September 4, 2006, p.122

DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 821
? S VIBRIO
S7 111474 VIBRIO
? DS

Set	Items	Description
S1	0	VIBRIO ADJ CHOLERA
S2	120459	TABLET
S3	49490	VIBRIO (W)CHOLERA
S4	37	S2 AND S3
S5	22	RD (unique items)
S6	0	K/3/1,7 AND 6
S7	111474	VIBRIO
? S S2 AND S7		
	120459	S2
	111474	S7
S8	58	S2 AND S7
? RD	40	RD (unique items)
? S KILLED OR INACTIVATED		
	288867	KILLED
	206237	INACTIVATED
S10	490219	KILLED OR INACTIVATED
? S S9 AND S10		
	40	S9
	490219	S10
S11	10	S9 AND S10
? RD	10	RD (unique items)
? T S12/K/ALL		

>>>KWIC option is not available in file(s): 399

12/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Formulation in tablets of a cholera whole cells inactivated vaccine
candidate

...ABSTRACT: The aim of this work was to evaluate the presentation in oral
tablets of an inactivated cholera vaccine to avoid that inconveniences
during application. We have therefore compared inactivated cultures of

Untitled

Vibrio cholerae with tablets formulation vaccine. We obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of V cholerae inactivated cell remained unaltered in the final tablet formulation. The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable...

DESCRIPTORS:

...ORGANISMS: Vibrio cholerae (Vibrionaceae)

12/K/2 (Item 1 from file: 45)
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

...B subunit of cholera toxin (CTB), similar to heat-labile toxin of ETEC, (2) formalin-killed whole cell ETEC H10407 (FK-ETEC), (3) crude preparation of colonization factor antigen I (CFA...)

...antigens. Conclusion: Microencapsulation appears to be a suitable approach for oral vaccination against ETEC and Vibrio cholerae.

DESCRIPTORS:

...linked immunosorbent assay; immune response; Western blotting; microencapsulation; adrenal cell; vaccination; antibody detection; enteric coated tablet; animal model; animal experiment; nonhuman; Gram negative infection; steroidogenesis; whole cell; Vibrio cholerae; digestion; bacterium; immunization; intestine lymphatic tissue; heat

12/K/3 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

...been proven to be safe and effective in the treatment and prophylaxis of TD. The tablet form has removed the inconvenience of previously required luggage space. Doxycycline, trimethoprim/sulphamethoxazole, trimethoprim and...

...would be adversely affected by diarrhoea, or travellers with unaffordable temporary incapacity. A new oral-killed whole-cell and B-subunit cholera toxin vaccine was demonstrated to induce protection against severe...

MEDICAL DESCRIPTORS:

...shigella; south and central america; stevens johnson syndrome--side effect--si; tinnitus--side effect--si; vibrio

12/K/4 (Item 1 from file: 135)
DIALOG(R)File 135:(c) 2007 NewsRx. All rts. reserv.

...for several years, primarily in traveler populations. The licensure in the European Union of a killed whole-cell cholera vaccine combined with the recombinant B subunit of cholera toxin (rCTB-WC...)

...Mortimer Market, Capper Street, London WC1E 6AU, England.
david.hill@uclh.org.

Study 2: An inactivated cholera vaccine developed in oral tablet formulation is antigenic and immunogenic.

According to recent research published in the journal Vaccine, "Licensed..."

...The aim of this work was to evaluate the presentation in oral tablets of an inactivated cholera vaccine to avoid that inconveniences during application."

"We have therefore compared inactivated cultures of vibrio cholerae with tablets formulation vaccine.

Untitled

"we obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of *V. cholerae* inactivated cell remained unaltered in the final tablet formulation," said A. Talavera and colleagues at Finlay Institute in Cod.

The authors concluded, "The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable..."

...and colleagues published their study in Vaccine (Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Vaccine, 2006;24(16):3381-3387).

For additional information, contact A. Talavera, Finlay...

...from China, "The cholera toxin (CT) genes ctxAB are carried on a lysogenic phage of *Vibrio cholerae*, CTX Phi, which can transfer ctxAB between toxigenic and nontoxigenic strains of bacteria. This...

...kanb@btamail.net.cn.

Keywords: Beijing, China, Cholera Vaccine, Vaccine Development, Vaccine Efficacy, Immunology, Immunotherapy, *Vibrio cholerae*, Proteomics.

This article was prepared by Gastroenterology Week editors from staff and other reports...

...DESCRIPTORS: U.K.; Preventive Medicine; Proteomics; Travel Health; Travel Immunization; Travel Vaccination; Vaccine Development; Vaccine Efficacy; *Vibrio cholerae*; All News

12/K/5 (Item 2 from file: 135)
DIALOG(R)File 135:(c) 2007 NewsRx. All rts. reserv.

Inactivated cholera vaccine in oral tablet form is antigenic and immunogenic

TEXT: An inactivated cholera vaccine developed in oral tablet formulation is antigenic and immunogenic.

According to recent research published in the journal Vaccine, "Licensed..."

"The aim of this work was to evaluate the presentation in oral tablets of an inactivated cholera vaccine to avoid that inconveniences during application."

"we have therefore compared inactivated cultures of *Vibrio cholerae* with tablets formulation vaccine."

"we obtained that antigenic activity (ELISA) and immunogenicity in animal model (ELISA and vibriocidal tests) of *V. cholerae* inactivated cell remained unaltered in the final tablet formulation," said A. Talavera and colleagues at Finlay Institute in Cod.

The authors concluded, "The results suggest that the oral tablet formulation could be a useful pharmaceutical form in order to produce a new and affordable..."

...and colleagues published their study in Vaccine (Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Vaccine, 2006;24(16):3381-3387).

For additional information, contact A. Talavera, Finlay...

...the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England.

Keywords: Cod, Cuba, Cholera Vaccine, *Vibrio cholerae*, Oral Tablets, Immunogenic & Antigenic.

This article was prepared by Anti-Infectives Week editors from...

Untitled

DESCRIPTORS: Cholera vaccine; City: Cod; Country: Cuba; Finlay Institute, Havana; Immunogenic & Antigenic; Immunology; Oral Tablets; Vibrio cholerae; All News; Professional News; All News; Professional News

12/K/6 (Item 1 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... for safety and effectiveness. (19)
Cholera. Cholera is a well known diarrheal disease caused by Vibrio cholera, acquired in humans through ingestion of contaminated water. The organism causes a profound secretory...

...cause similar watery diarrhea. Bacteriologic diagnosis of cholera diarrhea has been well studied for decades. Vibrio species can be seen and identified readily with darkfield or phase contrast microscopes. Culture will...

...drugs include ampicillin (250 mg every 6 hours for 5 days) and TMP-SMX (one tablet every 12 hours). Appropriate scale should be used for pediatric doses.

Prophylaxis. The currently available vaccine is a killed suspension of v. cholera. It provides incomplete protection and lasts for no longer than six...

...an aerosol exposure and subsequent pneumonic plague. The plague vaccine is a whole-cell, formalin-killed product. The usual dose is 0.5 mL given at weeks zero, one, and two...be used in the patient unable to take the other recommended medications.

Prophylaxis. A formalin inactivated whole-cell vaccine is available as an investigational drug in the United States and has...

...Mortal Wkly Rep.

Table 5. Vaccines for Biological Weapons

DISEASE

VACCINE

Anthrax

Three versions: Two killed, one live
Bacillus anthracis Appear equally effective in prevention (about 90%)
Untested (in the United...

...Somewhat effective against bubonic plague
version.

Pneumonic plague treated with antibiotics.

Rift Valley fever
and live-attenuated Rift Valley

Both inactivated
fever vaccines currently are under investigation.

Smallpox
1997;46: 267-269.

Given prior to...zoonoses. J Med Microbiol

(20.) Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970;42:653-666.

(21.) Russel P...

12/K/7 (Item 2 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... 10.sup.6] organisms. As it takes [10.sup.8] organisms of E coli or
Page 12

Untitled

vibrio cholerae, [10.sup.5] of salmonella, and 10- [10.sup.2] of shigella to cause...

...volume of water. The bacteria thrived in the water, but the neat and diluted wine killed the cholera vibrios within 15 minutes.[14]

MECHANISM OF ACTION

It is not the alcohol...Helminger A, Witassek F, Manhart MD, et al. Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agent Chemother 1986;29:625-7. [3] Sox TE, Olson

...

12/K/8 (Item 3 from file: 149)
DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

... 15 years, just a few bacteria (enterotoxigenic Escherichia coli, enteropathogenic E coli, Shigella spp, and Vibrio cholerae O1) and one virus (rotavirus) combine to cause a substantial proportion of the diarrhoeal...

...or, at least, safe and immunogenic.

Vaccines against typhoid fever

Although the old heat-phenol- inactivated or acetone- inactivated S typhi whole-cell parenteral vaccines confer useful protection against typhoid fever, they are unpopular with children and travellers because of frequent systemic and local adverse reactions. Inactivated preparations of S typhi given orally are well tolerated but give little or no protection

...

...or placebo within one week; [2] a few minutes beforehand they chewed a 1 g tablet of [NaHCO₃] to neutralise gastric acid. During 3 years of surveillance, protective efficacy...

...on typhoid vaccines

Both Ty21a and Vi polysaccharide offer modern alternatives to the poorly tolerated killed whole-cell parenteral vaccines. Despite the lack of information on efficacy in children under 4...no Shiga vaccines seem to be ready for clinical trials.

Vaccines against cholera

The Old inactivated whole-cell parenteral cholera vaccines can protect older children and adults in endemic areas for...

...were recently tested concomitantly in a placebo-controlled field trial in Bangladesh: one consists of killed whole V cholerae O1 (both serotypes and biotypes) and the other of whole vibrios in...

...the cumulative protective efficacy was essentially identical for the two vaccines--about 50%. [12]

The inactivated oral vaccines represent an improvement in protection against cholera, confirm the rationale for oral immunisation... were significantly higher than those recorded after three spaced oral doses of the B subunit/ killed whole-cell oral vaccine. [14] A single dose of CVD 103 or CVD 103-HgR...

...field trial is indicated in young children.

Summary comment on cholera vaccines

The well tolerated inactivated oral vaccines recently field-tested in Bangladesh, by protecting older children and adults for at least 3 years, represent an important advance in immunoprophylaxis against cholera. The drawbacks of the inactivated vaccines, including poor protection of young children and a requirement for multiple doses, can perhaps be overcome by a live cholera vaccine. Both the inactivated oral cholera vaccine and attenuated strain CVD 103-HgR are likely to become available

Untitled

soon for immunisation of adult travellers. In the short term, however, only the inactivated vaccine will be available for cholera control in endemic areas.

Vaccines against enterotoxigenic E coli...

...antitoxin after natural infection.

The vaccine candidates include non-living antigen vaccines (toxoids, mixtures of inactivated whole bacteria, and purified surface antigens) and several live oral vaccines. [15] Prototypes of some...

...There is a strong antigenic similarity between LT and cholera toxin, and in Bangladesh the killed whole- vibrio /B subunit combination oral cholera vaccine significantly protected against diarrhoea due to LT-producing E...

...they protected protein antigens from gastric juice, could renew interest in this type of vaccine.

Killed fimbriated whole E coli with or without toxoid

Inactivated fimbriated whole E coli bacteria, given alone or with toxoid, are also being investigated as...

12/K/9 (Item 4 from file: 149)

DIALOG(R)File 149:(c) 2008 The Gale Group. All rts. reserv.

...ABSTRACT: to the World Health Organization by 35 countries. Untreated cholera, due to various strains of Vibrio cholerae O1 (VC), can result in fatality rates of 40 percent. It is estimated that...

...include antigens representative of these components to facilitate immune responses. Candidate vaccines include an oral inactivated whole-cell purified antigen, live carrier bacteria vaccines, Colicin-E2 treated whole cell vaccine, and...

... effective oral vaccines based on nonliving organisms and antigens, or on live, attenuated strains of Vibrio cholerae O1. the meeting discussed the results that have recently emerged from such studies, including a field of two formulations of an inactivated oral cholera vaccine in Bangladesh> research on protective antigens of V. cholerae O1 that might lead to improved inactivated vaccines> and studies of the safety, immunogenicity, and efficacy of live cholera vaccines in volunteers...

...immune response against one or more relevant antigens of V. cholerae O1.

Important antigens of Vibrio cholerae O1

Studies in animals and humans have shown that V. cholerae cell-wall lipopolysaccharide...other potentially important ToxR-regulated antigens during the preparation of whole-cell (WC)vaccines.

The killed oral vaccines recently tested in Bangladesh (see below) contain no detectable TCP by Western blot...

...ensure the expression and preservation of TCP and other ToxR-regulated antigens.

Candidate oral vaccines

Killed WC and WC+BS (WC/BS) vaccines. Killed whole-cell vaccines with or without the B subunit of cholera toxin have recently been...

...oral WC/BS vaccine contains purified B subunit from cholera toxin and formalin- or heat- inactivated classical and El Tor cholera vibrios of the Inaba and Ogawa serotypes. Purified BS is...

...of this subunit to bind to cell membranes may contribute to its immunogenicity. The heat- killed organisms in the vaccine provide Inaba and Ogawa LPS antigens, and the formalin- killed organisms provide heat-labile antigens. Because the BS pentamer is acid labile, the vaccine is...

Untitled

...by WHO and other agencies, initiated a randomized, double-blind, placebo-controlled field trial of killed oral cholera vaccines at its Matlab field area. In this trial, a total of 63...

...at 6-week intervals of WC/BS vaccine, WC vaccine, or a placebo consisting of killed E. coli strain K12. Each dose of WC/BS contained 1 mg of BS plus 1×10^{11} killed V. cholerae O1 whole cells, consisting of heat-killed classical Inaba (Cairo 48), heat-killed classical Ogawa (Cairo 50), formalin-killed El Tor Inaba (Phil 6973), and formalin-killed classical Ogawa (Cairo 50) serotype, in equal proportions. The WC vaccine had the same cellular...residual toxicity and to determine the best mode of delivery (either as components of a killed vaccine or as the products of live, attenuated bacterial vectors).

Determinants of immunity to ETEC...provides further encouragement to seek ways of achieving active immunity with oral vaccines.

Candidate vaccines

Inactivated whole-cell purified antigen vaccine. Research is being carried out on an oral vaccine against ETEC that would consist of killed E. coli bacteria representing the major O-groups associated with ST/LT production and expressing...

...retention of 50-100% of the antigenicity of the different colonization factors. The CFA's of inactivated organisms are stable at 4 [degrees]C for at least 8 months and when incubated...

...endonuclease that enters the cell by means of receptors on sensitive strains of E. coli. Killed bacteria exhibit no change in their antigenicity or concentrations of LT enterotoxin, CFA/I, or...

...Two oral doses of 3×10^{10} freshly prepared colicin-[E. sub.2]-killed E. coli strain H10407 given 1 month apart induced both serum IgG and intestinal IgA...

...increased levels of these antibodies. To evaluate the protection induced by colicin-[E. sub.2]-killed organisms, groups of 9 or 10 subjects, consisting of approximately equal numbers of vaccinees and...

...protection was demonstrated 6-8 months after vaccination. Methods of preserving colicin-[E. sub.2]-killed E. coli have not yet been developed. Avirulent salmonellae as carriers for ETEC antigens. With...LT-BS responses than mice not previously immunized with the vector.

Research recommendations

Cholera vaccines

Killed oral whole-cell vaccine. Further research on cholera WC vaccine should seek to increase its...

...or hyper-produce the B subunit. a practical vaccine formulation, possibly a capsule or soluble tablet that is stable at ambient temperatures, should be developed.

Live oral cholera vaccine. The objective...

...efficacy in adults and their safety and immunogenicity in adults and children. The efficacy of killed whole-cell vaccine and live strains should be compared in volunteers. The transmissibility to non...

...should be defined and an attempt made to identify and characterize the responsible antigen(s). Killed whole-cell vaccines should be prepared by methods that are known to preserve such antigens in immunogenic form.

Killed oral whole-cell vaccines. Research to develop a safe and effective killed oral WC vaccine for ETEC diarrhoea should continue. Bacteria that represent the most important ETEC...of one or several foreign antigens by this vector.

Mucosal adjuvants. The development of efficient killed oral

Untitled
vaccines for cholera and ETEC diarrhoea, as well as other oral or topical
vaccines...
? DS

Set	Items	Description
S1	0	VIBRIO ADJ CHOLERAЕ
S2	120459	TABLET
S3	49490	VIBRIO (W)CHOLERAЕ
S4	37	S2 AND S3
S5	22	RD (unique items)
S6	0	K/3/1,7 AND 6
S7	111474	VIBRIO
S8	58	S2 AND S7
S9	40	RD (unique items)
S10	490219	KILLED OR INACTIVATED
S11	10	S9 AND S10
S12	10	RD (unique items)

? LOGOFF

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5260	vibrio adj cholera or vibrio adj cholerae	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:36
L3	116465	inactivated or inactivate	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:37
L4	78603	povidone or gerlatin or carboxymethylcellulose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:38
L5	356241	carboxymethylstarch or magnesium adj stearate or silicon adj dioxide or talc	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:39
L6	174151	cellulose adj acetophthalate or cellulose adj diethylphthalate or lacquer or titanium adj dioxide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:40
L7	165499	lactose or cornstarch	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:40
L8	526400	sosium adj croscarmelose or cellulose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:43
L9	316445	tablet or capsule or pill	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:42

EAST Search History

L10	1523	I1 and I9	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:42
L11	976	I10 and I3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:27
L12	45	I11 and I4 and I5 and I6 and I7 and I8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:42
L13	526400	sodium adj croscarmelose or cellulose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:43
L14	45	I11 and I4 and I5 and I6 and I7 and I13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 09:43
L15	65972	vaccine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:27
L16	2636	I1 and I15	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:27
L17	1517524	whole	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:28

EAST Search History

L18	1454	I16 and I3 and I17	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:28
L19	173823	tablet	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:28
L20	626	I18 and I19	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:29
L21	5	I20 and I4 and I5 and I6 and I7 and I13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:33
L22	744	I16 and I19	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 10:57
L23	2	"5827534".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:13
L24	4	o139 and o1 and e1 adj tor and classic and ogawa and inaba	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:46
L25	136266	attenuated or attenuate	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:26

EAST Search History

L26	173823	tablet	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:26
L27	296626	oral	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:26
L28	408065	bacteria or bacterial	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:26
L29	2440	I25 and I26 and I27 and I28	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:27
L30	7289	I4 and I5 and I6 and I7 and I13	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:28
L31	107	I29 and I30	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:53
L32	13394	cholera	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:28
L33	16	I31 and I32	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:28

EAST Search History

L34	1859870	coating	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:47
L35	26382	I26 and I27 and I34	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:48
L36	1	lacquer and acetophthalate and diethylphthalate and titanium adj dioxide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:49
L37	1172	lacquer and I35	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:49
L38	36655	enteric	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:56
L39	0	entericgastric	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:56
L40	67915	gastric	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:57
L41	46974	I38 or I40 and I26 and I27	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 11:57

EAST Search History

L42	36655	I38 or I40 and I26 and I27 and I36	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 12:55
L43	2	"4873090".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	NEAR	OFF	2008/01/07 12:56